<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01940770</url>
  </required_header>
  <id_info>
    <org_study_id>D5551C00001</org_study_id>
    <secondary_id>EUPAS18608</secondary_id>
    <nct_id>NCT01940770</nct_id>
  </id_info>
  <brief_title>Specific Clinical Experience Investigation for Long-term Use of Bydureon.</brief_title>
  <official_title>Specific Clinical Experience Investigation for Long-term Use of Bydureon Subcutaneous Injection 2 mg and Bydureon Subcutaneous Injection 2 mg PEN</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To confirm the safety and efficacy of Bydureon in long-term use in Japanese patients with
      type 2 diabetes mellitus under actual drug use.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To confirm the safety and efficacy of Bydureon (hereinafter referred to as Bydureon) in
      long-term use in Japanese patients with type 2 diabetes mellitus under actual drug use.

        1. Primary Objective To confirm the safety profile in Japanese patients with type 2
           diabetes mellitus receiving Bydureon under daily practices.

        2. Secondary objective As the secondary objective of this S-CEI, the following items are to
           be investigated.

             -  Frequencies of AEs related to cardiovascular events, hypoglycaemia, digestive
                symptoms, and injection site reaction.

             -  Development of pancreatitis, renal impairment (especially acute renal failure),
                hypersensitivity reaction, and malignant tumour (especially thyroid tumour and
                pancreatic malignancy)

             -  Safety in patients with mild or moderate renal impairment

             -  Changes of weight, blood pressure, pulse rate, fasting blood sugar, fasting
                insulin, HbA1c, and blood lipids

             -  Bydureon administration under daily practices focusing on the patient's
                demographics and clinical characteristics of diabetes mellitus (duration of
                diabetes mellitus, treatment duration, complications, Bydureon administration, etc)

             -  Anti-exenatide antibody titer in AE cases (hypersensitivity, loss of control of
                blood sugar)
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">October 18, 2013</start_date>
  <completion_date type="Anticipated">April 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse event incidence</measure>
    <time_frame>3 years</time_frame>
    <description>Number of Adverse Drug Reactions</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean change of HbA1c</measure>
    <time_frame>from baseline up to 3 years</time_frame>
    <description>Change value of HbA1c from baseline as mean.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change of weight</measure>
    <time_frame>from baseline up to 3 years</time_frame>
    <description>Change value of weight from baseline as mean.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change of blood pressure</measure>
    <time_frame>from baseline up to 3 years</time_frame>
    <description>Change value of blood pressure from baseline as mean.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change of lipid metabolism</measure>
    <time_frame>from baseline up to 3 years</time_frame>
    <description>Change value of lipid metabolism from baseline as mean.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change of HbA1c</measure>
    <time_frame>from baseline up to 3 years</time_frame>
    <description>Change value of HbA1c from baseline as median.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change of HbA1c</measure>
    <time_frame>from baseline up to 3 years</time_frame>
    <description>Change value of HbA1c from baseline as minimum.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change of HbA1c</measure>
    <time_frame>from baseline up to 3 years</time_frame>
    <description>Change value of HbA1c from baseline as max.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change of weight</measure>
    <time_frame>from baseline up to 3 years</time_frame>
    <description>Change value of weight from baseline as median.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change of weight</measure>
    <time_frame>from baseline up to 3 years</time_frame>
    <description>Change value of weight from baseline as minimum.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change of weight</measure>
    <time_frame>from baseline up to 3 years</time_frame>
    <description>Change value of weight from baseline as max.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change of blood pressure</measure>
    <time_frame>from baseline up to 3 years</time_frame>
    <description>Change value of blood pressure from baseline as median.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change of blood pressure</measure>
    <time_frame>from baseline up to 3 years</time_frame>
    <description>Change value of blood pressure from baseline as minimum.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change of blood pressure</measure>
    <time_frame>from baseline up to 3 years</time_frame>
    <description>Change value of blood pressure from baseline as max.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change of lipid metabolism</measure>
    <time_frame>from baseline up to 3 years</time_frame>
    <description>Change value of lipid metabolism from baseline as median.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change of lipid metabolism</measure>
    <time_frame>from baseline up to 3 years</time_frame>
    <description>Change value of lipid metabolism from baseline as minimum.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change of lipid metabolism</measure>
    <time_frame>from baseline up to 3 years</time_frame>
    <description>Change value of lipid metabolism from baseline as max.</description>
  </secondary_outcome>
  <enrollment type="Actual">1137</enrollment>
  <condition>Type 2 Diabetes</condition>
  <eligibility>
    <study_pop>
      <textblock>
        The patients with type 2 diabetes mellitus who will be given Bydureon for the first time
        and who inadequately respond to sulfonylurea, biuguanides, and/or thiazolidines
        (monotherapy or combination use) in addition to diet and exercise.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        - The patients with type 2 diabetes mellitus who inadequately respond to sulfonylurea,
        biuguanides, and/or thiazolidines (monotherapy or combination use) in addition to diet and
        exercise.

        Exclusion Criteria:

          -  No past history of hypersensitivity to the components of Bydureon.

          -  Not the patient with diabetic ketoacidosis, diabetic coma/ precoma, and/ or type 1
             diabetes mellitus.

          -  Bydureon will not be administered to the patient in an emergency situation such as
             severe infection and operation.

          -  Not the patient with severe renal impairment, including those receiving dialysis.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shigeru Yoshida, MD</last_name>
    <role>Study Director</role>
    <affiliation>Quality &amp; Safety Compliance Office</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Aichi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Akita</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Aomori</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chiba</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ehime</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Fukui</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Fukuoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Fukushima</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Gifu</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Gunma</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hiroshima</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hokkaido</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hyogo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ibaraki</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ishikawa</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Iwate</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kagawa</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kagoshima</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kanagawa</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kochi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kumamoto</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kyoto</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Mie</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Miyagi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Miyazaki</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nagano</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nagasaki</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nara</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Niigata</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Oita</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Okayama</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Okinawa</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Saga</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Saitama</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Shiga</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Shimane</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Shizuoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tochigi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tokushima</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tottori</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Toyama</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Wakayama</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Yamagata</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Yamaguchi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Yamanashi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 9, 2013</study_first_submitted>
  <study_first_submitted_qc>September 9, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 12, 2013</study_first_posted>
  <last_update_submitted>April 11, 2018</last_update_submitted>
  <last_update_submitted_qc>April 11, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 12, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Diabetes Mellitus(DM)</keyword>
  <keyword>Bydureon</keyword>
  <keyword>Exenatide</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Exenatide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

